Skip to content
TrialMatch
Sign up
Recruiting

Prostate Cancer Genetic Risk Evaluation and Screening Study

Create a profile to match View the full record on ClinicalTrials.gov

About this study

This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or Black/African ancestry and evaluate the utility of prostate MRI as a screening tool. The hypothesis is that this targeted population of men are at elevated risk of developing prostate cancer compared to the general population, and enhanced screening with MRI will enable early detection and diagnosis of potentially aggressive prostate cancer, characterization of the penetrance of specific mutations, and potentially identify new genetic risk mutations.

Condition
Prostatic Neoplasm, Prostate Cancer, BRCA2 Mutation, BRCA1 Mutation, ATM Gene Mutation, MMR Mutation, Lynch Syndrome, Genetic Predisposition to Disease
Tested
Prostate cancer screening
Sponsor
Massachusetts General Hospital

Who can join

Age
35 to 74 years
Sex
Male only
Healthy volunteers
Not accepted

Inclusion 11

  • Minimum age: 35 years
  • Maximum age: 74 years
  • Eligible sex: Male
  • Study condition: Prostatic Neoplasm, Prostate Cancer, BRCA2 Mutation, BRCA1 Mutation, ATM Gene Mutation, MMR Mutation, Lynch Syndrome, Genetic Predisposition to Disease
  • Men 35-74 years old
  • No known diagnosis of prostate cancer
  • Life expectancy \>10 years
  • Meet cohort A, B, or C criteria
  • Cohort A: Documented pathogenic or likely pathogenic germline genetic mutation in a prostate cancer risk gene from a CLIA-certified laboratory (ATM, ATR, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, FANCA, GEN1, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53)
  • Cohort B: A strong family history suggestive of high genetic risk for prostate cancer with negative clinical genetic testing
  • Cohort C: Individuals who self-identify as Black American or Black Caribbean with both parents and all four grandparents of Black/African ancestry

Exclusion 3

  • Prior diagnosis or treatment of prostate cancer
  • Inability to undergo prostate MRI
  • Inability to receive MRI contrast agent

Where

1 site, 1 recruiting

Massachusetts General Hospital

Boston, Massachusetts, United States

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.